All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

The largest GWAS study on BMI including a total of 339,224 individuals identified 97 genetic loci associated with increased BMI \[[@pone.0125660.ref001]\]. One chromosomal region (chr16p11.2) is tagged by two lead SNPs separated by more than 500 kb. One of the SNPs (3888190) is located near *ATP2A1* (ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 gene) and *SH2B1* (Src-homology 2B adaptor protein 1 gene), the other signal (rs2650492) is near *SBK1* (SH3 domain binding kinase 1 gene) and *APOBR* (apolipoprotein B receptor gene). Both tag a large region with high linkage disequilibrium (LD) which has solidly been replicated for obesity and BMI \[[@pone.0125660.ref002]--[@pone.0125660.ref014]\]. Besides the GWAS findings, a large deletion in the same chromosomal region 16p11.2 was associated with obesity \[[@pone.0125660.ref015]--[@pone.0125660.ref020]\], developmental delay and autism \[[@pone.0125660.ref015]--[@pone.0125660.ref019]\]. The reciprocal duplication of the same chromosomal region is associated with reduced BMI, developmental delay and schizophrenia \[[@pone.0125660.ref021]\].

The most plausible obesity gene in the region is *SH2B1*. SH2B1 is a mediator of energy homeostasis and increases leptin and insulin potency in downstream signaling pathways \[[@pone.0125660.ref022]\]. *Sh2b1* knockout mice are obese, hyperphagic and exhibit traits of the metabolic syndrome like hyperlipidemia, leptin resistance, hyperglycemia, and insulin resistance \[[@pone.0125660.ref023]\]. In *SH2B1* we detected a rare mutation solely in obese individuals; additionally we replicated the obesity association of the GWAS SNP rs7498665 (*SH2B1*: p.Thr484Ala; \[[@pone.0125660.ref014]\]). Another group also described *SH2B1* mutations in extremely obese children with insulin resistance \[[@pone.0125660.ref024], [@pone.0125660.ref025]\]. As the infrequent mutations cannot explain the genome-wide association signal and so far, no functional effect of the frequent SNP has been detected \[[@pone.0125660.ref014], [@pone.0125660.ref025]\], we analysed additional promising obesity candidate genes in the same chromosomal region.

Lead SNPs in GWAS can tag large regions of high linkage disequilibrium (LD) which can comprise one to several genes/variants that are relevant for the analyzed phenotype \[[@pone.0125660.ref026]\]. For the region on chr16p11.2, Speliotes et al. \[[@pone.0125660.ref002]\] listed non-synonymous SNPs in adjacent genes (*SH2B1*, *APOBR*, *SULT1A2*) in high LD (r^2^\>0.75) with the lead SNP rs7359397 (\[[@pone.0125660.ref002]\], see supplementary material). Additionally for a total of four adjacent genes, involvement in weight regulation seems likely because they are either (a) biological candidates (*SH2B1*), or differentially expressed in adipose tissue between general population and patients who underwent bariatric surgery (*SH2B1*, *SULT1A1*, *SULT1A2*, *TUFM*; \[[@pone.0125660.ref001]\]). Further fine mapping of the chromosomal region for causal variants that contribute to the obesity association has not yet been undergone.

The *APOBR* gene encodes a macrophage receptor that regulates fat and vitamin uptake into cells \[[@pone.0125660.ref027], [@pone.0125660.ref028]\]. Non-synonymous variants (rs180743: p.Pro428Ala and rs3833080: p.Gly369_Asp370del9) in *APOBR* are associated with hypercholesterolemia \[[@pone.0125660.ref029]\]. Mice fed a high fat diet until they became obese showed increased expression of *APOBR* and hence increased lipid intake in macrophages of the adipose tissue \[[@pone.0125660.ref028]\]. This is mediated by the transcription factors PPARα, PPARβ/δ, PPARγ and the PPAR-RXR transcriptional complex \[[@pone.0125660.ref030], [@pone.0125660.ref031]\]. In normal weight humans, a single meal with high fat content (72% of the total energy of the meal) increased both *APOBR* expression and lipid uptake in monocytes \[[@pone.0125660.ref032]\]. High blood lipid levels differentially regulate *APOBR* expression in human postprandial monocytes and macrophages and lead to foam cell formation \[[@pone.0125660.ref033]\].

The sulfotransferase genes *SULT1A1* and *SULT1A2* are located close to each other on chr16p11.2. Both proteins sulfonate hormones like estrogens, estrogenic alkylphenols, 17-β-estradiol and several androgens, so that the hormones can be excreted \[[@pone.0125660.ref034]\]. Obesity is associated with increased levels of 17-β-estradiol, estron and estron sulfate which are substrates of SULT1A2 \[[@pone.0125660.ref035]--[@pone.0125660.ref037]\]. Childhood obesity is associated with an increased risk of adult obesity and Type 2 Diabetes mellitus \[[@pone.0125660.ref038]\]. Association of a non-synonymous SNP (rs141581853: *SULT1A1* p.Arg213His) with obesity but not hypertension had been described \[[@pone.0125660.ref039]\]. The regulation of *SULT1A1* expression in diet induced obesity (DIO) rats in adipose tissue and liver was dependent on the dietary fat content \[[@pone.0125660.ref040]\].

*TUFM* encodes a transcription factor for mitochondrial gene expression \[[@pone.0125660.ref041]\]. (1) Exclusive maternal inheritance of mitochondria and mitochondrial DNA, (2) stronger correlation with maternal than paternal BMI \[[@pone.0125660.ref042]\] and (3) the relevance of mitochondria for energy metabolism indicate that genes involved in mitochondrial function are relevant candidate genes for weight regulation. *TUFM* expression is up regulated in DIO rats on a high fat diet \[[@pone.0125660.ref040]\]. In human cultured hippocampal neurons, BDNF stimulation down regulated the expression of *TUFM* \[[@pone.0125660.ref043]\].

In order to fine map the chromosomal region chr16p11.2 for further obesity associated variants, we screened the coding regions of *APOBR*, *SULT1A1*, *SULT1A2*, and *TUFM* for variants in 95 extremely obese children and adolescents. Most of these individuals were enriched for the likely presence of mutations in high LD with the original obesity association signal \[[@pone.0125660.ref002], [@pone.0125660.ref014]\]. Our focus was the detection of common to infrequent variants (MAF \> 0.01) which affect the protein sequence. Previously it was shown, for instance for the MC4R, that GWAS results point to genes in which functionally relevant mutations are found more frequently in cases than in controls \[[@pone.0125660.ref044]\]. These infrequent mutations might also have a major gene effect. Although synthetic association does not seem to be a frequent mechanism \[[@pone.0125660.ref045]\], GWAS results and mutation screens frequently depict the same genes. Subsequently, we confirmed the detected non-synonymous variants in independent study groups.

Material and Methods {#sec006}
====================

Study groups {#sec007}
------------

An overview of the study groups can be found in [Table 1](#pone.0125660.t001){ref-type="table"} (see also \[[@pone.0125660.ref014]\]), details of recruitment have been described previously \[[@pone.0125660.ref046], [@pone.0125660.ref047]\]. We included children and adolescents (mean age = 13.25 ± 3.26 years) with a BMI above the 97th BMI percentile. Written informed consent was given by all participants and in case of minors by their parents. These studies were approved by the Ethics Committees of the respective Universities (Marburg: 'Ethik-Kommission des Fachbereichs Medizin der Philipps-Universität Marburg': ethic commission of the Medical Faculty of the Philipps-University Marburg, Duisburg-Essen: 'Ethik-Kommission der Medizinischen Fakultät der Universität Duisburg-Essen': ethic commission of the Medical Faculty of the University of Duisburg-Essen) and were performed in accordance with the Declaration of Helsinki.

10.1371/journal.pone.0125660.t001

###### Phenotypic description of analyzed study groups.

![](pone.0125660.t001){#pone.0125660.t001g}

                                                      \% male        age            BMI            BMI SDS
  ----------------------------------- ------- ------- -------------- -------------- -------------- -------------
  **Screening Sample**                Cases   95      48.89          13.25 ± 3.26   31.79 ± 5.13   4.06 ± 5.13
  **Family-based GWAS for obesity**   Cases   615     45.11          13.44 ± 3.02   32.02 ± 5.82   4.23 ± 1.96
  Parents                             1,230   50.00   42.54 ± 6.02   30.28 ± 6.33   1.65 ± 1.84    
  **DAPOC**                           Cases   1,383   44.25          10.79 ± 2.84   27.82 ± 5.13   3.11 ± 1.58
  **Case-control GWAS for obesity**   Cases   453     42.60          14.37 ± 3.75   33.15 ± 6.68   4.51 ± 2.15
  Controls                            435     39.08   26.08 ± 5.75   18.09 ± 1.14   -1.45 ± 0.35   

Mutation screen sample: part of the family-based and the case-control GWAS samples' cases (90 extremely obese index patients from the 705 family-based GWAS trios; 5 extremely obese patients from the case-control GWAS). Family-based GWAS sample: 615 index patients with extreme obesity and their biological parents; independent of initial screening sample \[[@pone.0125660.ref014], [@pone.0125660.ref046]\]. The 355 trios used for association analysis was part of this sample but did not deviate significantly from the description given for the overall sample. Case-control GWAS sample: GWAS of extremely obese children and adolescents in comparison to lean, adult controls; independent of initial screening sample \[[@pone.0125660.ref014], [@pone.0125660.ref047]\]. DAPOC: Datteln Paediatric Obese Cohort: Sample of overweight and obese children and adolescents; independent of initial screening sample \[[@pone.0125660.ref054]\].

Mutation screen {#sec008}
---------------

The selection of extremely obese individuals for the mutation screen was based on genotypes at SNP rs2008514 (proxy of rs7359397; \[[@pone.0125660.ref002]\]) in the chromosomal region 16p11.2. In total, we analyzed 95 extremely obese individuals, 90 of whom were likely enriched for the presence of infrequent mutations at chr16p11.2 that contribute to the association signal of rs2008514. These extremely obese patients (offspring) from the family-based GWAS sample were homozygous for the obesity risk allele T at rs2008514 and had at least one heterozygous parent, thus substantially contributing to the observed over-transmission of the rs2008514 T-allele in our previous study \[[@pone.0125660.ref020]\]. The other five individuals harbor a deletion on chr16p11.2 that does not include the genes which were screened for mutations here. The 95 individuals were screened for mutations in *APOBR* (NM ID: 55911, chr16:28,505,970--28,510,291), *SULT1A1* (NM ID: 6817, chr16:28,617,142--28,620,176), *SULT1A2* (NM ID: 6799, chr16:28,603,349--28,607,251) and *TUFM* (NM ID: 7284, chr16:28,854,296--28,857,590, positions given for GRCh37/hg19). All primers can be found in ([S3 Table](#pone.0125660.s003){ref-type="supplementary-material"}).

Depending on the size of the screened fragment, one of the following two methods was used for the mutation screen of the coding region of each gene as described previously \[[@pone.0125660.ref014], [@pone.0125660.ref048]\]: We used single stranded conformation polymorphism analyses for PCR amplicons up to 300bp \[[@pone.0125660.ref049]\] or denaturing high-performance liquid chromatography for PCR amplicons up to 600bp \[[@pone.0125660.ref050], [@pone.0125660.ref051]\]. Using these fragment sizes both methods achieve a high sensitivity (below 5% error rate \[[@pone.0125660.ref049], [@pone.0125660.ref050]\]) which is very well compatible with Sanger sequencing \[[@pone.0125660.ref052], [@pone.0125660.ref053]\]. All PCR amplicons with dHPLC/SSCP patterns deviant from the wild-type pattern were re-sequenced as described previously \[[@pone.0125660.ref014]\]. At least two experienced individuals independently assigned the deviant patterns; discrepancies were solved either by reaching consensus or by re-screening.

Genotyping {#sec009}
----------

The non-synonymous variants identified in the mutation screens in *SULT1A1*, and *SULT1A2* were genotyped in 355 obesity families \[[@pone.0125660.ref046]\] by MALDI TOF, RFLP and tetra ARMS PCR ([Fig 1](#pone.0125660.g001){ref-type="fig"}). The missense variants in *APOBR* (rs180743: p.Pro428Ala; rs3833080: p. Gly369_Asp370del9; rs368546180: p.Thr321_Gly329del9) were genotyped in the following independent study groups by either gel electrophoresis of PCR products (for deletions and insertions) or TaqMan assay (detailed information can be obtained from the authors): 615 obesity trios (extremely obese child or adolescent with both biological parents; \[[@pone.0125660.ref020]\]) and the case-control GWAS study groups (453 extremely obese cases and 435 lean controls described in \[[@pone.0125660.ref046], [@pone.0125660.ref047]\]; see above) and 1,383 obese and overweight children and adolescents (Datteln Paediatric Obese Cohort \[[@pone.0125660.ref054]\]). At least two experienced individuals independently assigned the genotypes; discrepancies were solved either by reaching consensus or by re-genotyping. In case of the trios, Mendelian inheritance was checked. For the other study groups, Hardy Weinberg equilibrium was assessed and fulfilled. All enzymes and protocols can be obtained from the authors.

![Decision tree for genotyping of variants detected in the initial screening collective of 95 extremely obese children and adolescents.](pone.0125660.g001){#pone.0125660.g001}

Statistics {#sec010}
----------

For association studies in the above-mentioned 453 cases and 435 controls Fisher's exact test (allelic association) was calculated with PLINK \[[@pone.0125660.ref055]\] adjusted for sex and age of the individuals. In the 615 trios, an asymptotic, 2-tailed p-value for the transmission disequilibrium test (TDT \[[@pone.0125660.ref056]\]) was calculated with PLINK. The initial screening sample was excluded from the further analyses. All p-values are asymptotic, two-sided and not corrected for multiple testing unless stated otherwise. Additionally to univariate analysis, we conducted a joint analysis of the significant SNPs to reveal if these SNPs descend from the same signal. This was done with R 3.1.0 \[[@pone.0125660.ref057]\] without any further adjustment.

Functional *in silico* analyzes {#sec011}
-------------------------------

All detected variants were analyzed for loss or gain of cryptic splice sites (ESEfinder \[[@pone.0125660.ref058]\], ESRSearch \[[@pone.0125660.ref059]\], RESCUE_ESE \[[@pone.0125660.ref060]\]), and transcription factor binding sites (TFSearch \[[@pone.0125660.ref061]\], Consite \[[@pone.0125660.ref062]\]). Prediction of an impact of an amino acid exchange on structure and function was performed by PANTHER \[[@pone.0125660.ref063]\], PolyPhen-2 \[[@pone.0125660.ref064]\], SNAP \[[@pone.0125660.ref065]\], PMUT \[[@pone.0125660.ref066]\], and MutationTaster \[[@pone.0125660.ref067]\]. For the InDel variants, PROVEAN \[[@pone.0125660.ref068]\] was used for functional prediction.

Results {#sec012}
=======

APOBR {#sec013}
-----

The mutation screen of the coding region of the *APOBR* in 95 extremely obese children and adolescents revealed 13 sequence variants (rs74949322, rs151233, rs149271, rs3833080, rs368546180, rs180743, rs180744, rs151174, rs40831, rs61738759, rs200751685, rs40833, and rs142786317; [S1 Table](#pone.0125660.s001){ref-type="supplementary-material"}). Three of these affect the amino acid sequence (rs368546180: p.Thr321_Gly329del9, rs3833080: p.Gly369_Asp370del9, and rs180743: p.Pro428Ala; [Table 2](#pone.0125660.t002){ref-type="table"}).

10.1371/journal.pone.0125660.t002

###### In silico functional prediction of detected non-synonymous variants in chr16p11.2 (screened genes APOBR, SH2B1, SULT1A1, and SULT1A2).

![](pone.0125660.t002){#pone.0125660.t002g}

                                                                                                                                  PolyPhen-2          SNAP          SIFT           Mutation Taster   PANTHER   PROVEAN                                               
  ----------------------------------- ---------------------------------------------- -------------------------------------------- ------------------- ------------- -------------- ----------------- --------- -------------- -------------- ------------- --------- ----
  ***APOBR***                         Thr321_Gly329 del9 *rs368546180*               c.933_934delA CAGCCTCAG GCGGGGAGG AGGCTGAA   NA                  NA            NA             Polymorphism      0.71      NA             deleterious    -3.0                    
  Gly369_Asp370 del9 *rs3833080*      c.1035_1036del GGGACAGCC TCAGGAGGG GAGGAGGCC   NA                                           NA                  NA            Polymorphism   1                 NA        neutral        -2.1                                   
  Pro428Ala *rs180743*                c.1282C\>G                                     0.600                                        possibly damaging   neutral       0.73           deleterious       0.78      Polymorphism   1              neutral       NA        
  ***SH2B1***                         Thr174Asn *rs181294111*                        g.2749C\>A                                   0.000               benign        neutral        0.53              neutral   0.31           Polymorphism   1             neutral   NA
  Thr484Ala *rs7498665*               g.8164A\>G                                     0.219                                        benign              neutral       0.85           neutral           0.93      Polymorphism   1              neutral       NA        
  Thr656Ile Pro675Ser *rs369858622*   9483C\>T                                       0.107                                        benign              not neutral   0.63           neutral           0.1       Polymorphism   0.96           NA            NA        
  0.038                               benign                                         neutral                                      0.53                neutral       0.43           Polymorphism      0.96      NA             NA                                     
  ***SULT1A2***                       Ile7Thr *rs1136703*                            c.20T/C                                      0.000               benign        neutral        0.06              neutral   0.68           Polymorphism   1             neutral   NA
  Pro19Leu *rs10797300*               c.56C/T                                        1.000                                        probably damaging   neutral       0.41           neutral           0.39      Polymorphism   0.99           deleterious   NA        
  Ser44Asn *rs145008170*              c.131G/A                                       0.021                                        benign              non-neutral   0.14           deleterious       0.03      Polymorphism   0.97           neutral       NA        
  Tyr62Phe *rs4987024*                c.185A/T                                       0.999                                        probably damaging   neutral       0.06           neutral           0.16      Polymorphism   0.99           NA            NA        
  Ala164Val *rs142241142*             c.491C/T                                       0.006                                        benign              neutral       0.60           neutral           0.21      Polymorphism   1              neutral       NA        
  Asn235Ile *rs1059491*               c.704A/C                                       1.000                                        probably damaging   non-neutral   0.81           deleterious       0         Polymorphism   0.04           NA            NA        

non-synonymous variants were not detected in *TUFM*; NA: not available. Data on *SH2B1* are obtained from our previous publication on a mutation screen in *SH2B1* \[[@pone.0125660.ref014]\] and displayed here to give a full overview on the mutations detected in the chromosomal region chr16p11.2 in the 95 screened obese individuals.

The common deletion rs3833080 (c.1036_1062del27; [S1 Data](#pone.0125660.s004){ref-type="supplementary-material"}) was present in each individual of the initial screen either hetero- or homozygously. The variant is located in the repeat region of *APOBR* with no predicted function and deletes one full repeat \[GlyGlyGluGluAlaGluThrAlaSer\] of the amino acid sequence \[[@pone.0125660.ref027]\]. *In silico* prediction for rs3833080 implicated no functional effect ([Table 2](#pone.0125660.t002){ref-type="table"}).

The non-synonymous, non-conservative SNP rs180743: p.Pro428Ala is located closely to the deletion rs3833080 which is in high LD with the variant (r^2^ = 0.98). Due to the high LD with rs2008514, both variants were carried, at least heterozygously, in all individuals of the initial screen. Functional *in silico* prediction for the risk allele is variable, although the SNP is located in a conserved position (conservation 66% among 29 species, ENSEMBL). SIFT and PolyPhen2 rated this SNP as deleterious, while PANTHER, SNAP and PMUT rated it as neutral ([Table 2](#pone.0125660.t002){ref-type="table"}). Although the overall prediction is "Polymorphism", Mutation Taster predicted the introduction of a new splice site, thereby disruption of a glutamate-rich region and potential loss of a phosphoserine domain ([Table 2](#pone.0125660.t002){ref-type="table"}).

The deletion rs368546180 with a length of 27bp (c.933_934insdel27; p.Ala328_Gly329) results in an in frame shortened amino acid sequence of the repeat region of *APOBR* with no predicted function \[[@pone.0125660.ref027]\]. The *in silico* prediction of the variant is ambiguous (Mutation Taster "Polymorphism", SIFT "neutral", PROVEAN "deleterious"; [Table 2](#pone.0125660.t002){ref-type="table"}). It was identified once heterozygously in an extremely obese child. The female mutation carrier (height 147 cm, weight 49 kg, BMI 22.68 kg/m^2^, BMI SDS 1.44, age 10.5 years, 93^rd^ age and sex specific BMI percentile) inherited the mutation from her obese mother (BMI 39.06 kg/m^2^) while the overweight (BMI 25.65 kg/m^2^) father did not harbor the deletion. The girl also homozygously carried the risk alleles (minor alleles) at rs180743: p.Pro428Ala and rs3833080: p.Gly369_Asp370del9.

Case-control association analyses based on 1,873 extremely obese cases and 435 lean controls were performed for the two frequent, coding variants rs180743: p.Pro428Ala and rs3833080: p.Gly369_Asp370del9 and the second infrequent deletion rs368546180: p.Thr321_Gly329del9. The *APOBR* rs180743 G-allele was nominally associated with obesity (odds ratio (OR) per allele = 1.27; 95% confidence interval (CI): 1.09--1.47, p = 0.002, see [Table 3](#pone.0125660.t003){ref-type="table"}). Similarly, the deletion allele of rs3833080 was nominally associated with obesity (OR = 1.25 per allele; 95%CI: 1.08--1.45, p = 0.003). Family-based association studies (based on 615 obesity trios) for rs3833080 and rs180743 confirmed these associations ([Table 3](#pone.0125660.t003){ref-type="table"}). While genotyping rs3833080 we also observed the insertion allele (p.Gly369_Asp370insGluGluAlaGlyThrAlaSerGlyGly), with a much lower frequency and exclusively in (extremely) obese cases (minor allele frequency of 0.001 in 2,540 cases) but not in 481 lean or normal weight controls. The second deletion rs368546180: p.Thr321_Gly329del9 was only observed once in all screened individuals. Consequently, association analysis could not be performed ([Table 3](#pone.0125660.t003){ref-type="table"}).

10.1371/journal.pone.0125660.t003

###### Association analyses of polymorphism of detected non-synonymous variants in chr16p11.2 (screened genes APOBR, SH2B1, SULT1A1, and SULT1A2) in extremely obese children and adolescents and lean controls.
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                                                                                           Alleles (% MAF[^a^](#t003fn001){ref-type="table-fn"})   Effect allele frequencies \[%\]           p-value (Bonferroni corrected)                                                                      
  --------------- -------------------------------------------------- --------------------- ------------------------------------------------------- --------------------------------- ------- -------------------------------- ------- ------- ---------- ------------------- ------------------- -------------------
  ***APOBR***     rs368546180[\*](#t003fn005){ref-type="table-fn"}   Thr321_Gly329del9     del9 (0.79)                                             \-                                NA      NA                               NA      NA      NA         NA                  NA                  NA
                  rs3833080                                          Gly369_Asp370del9     del9 (31.03)                                            \-                                46.06   43.36                            43.67   37.97   0.01       **0.004 (0.048)**   **0.002 (0.024)**   1.27 (1.09--1.47)
                  rs180743                                           Pro428Ala             G (38.96)                                               C                                 45.53   46.14                            43.68   38.26   1.70       **0.003 (0.036)**   **0.003 (0.036)**   1.25 (1.08--1.45)
  ***SH2B1***     rs181294111                                        Thr174Asn             A (0.05)                                                C                                 0.00    0.00                             0.00    0.00    0.00       0.317               1                   NA
                  rs7498665                                          Thr484Ala             G (38.14)                                               A                                 56.01   58.38                            40.52   35.63   0.00       **0.009** (0.108)   **0.001 (0.012)**   1.31 (1.13--1.52)
                  rs369858622                                        Thr656Ile Pro675Ser   T (0.01)                                                C                                 0.00    0.00                             0.00    0.00    0.00       1                   1                   NA
  ***SULT1A2***   rs4149403                                          Ile7Thr               C (NA)                                                  T                                 57.14   56.65                            NA      NA      0.00       0.634               NA                  NA
                  rs10797300                                         Pro19Leu              T (13.85)                                               C                                 11.90   11.71                            NA      NA      0.29       0.752               NA                  NA
                  rs145008170                                        Ser44Asn              NA (0.04)                                               NA                                \-      \-                               NA      NA      0.00       0.157               NA                  NA
                  rs4987024                                          Tyr62Phe              A (0.80)                                                T                                 98.45   98.37                            NA      NA      0.00       0.670               NA                  NA
                  rs142241142                                        Ala164Val             A (NA)                                                  G                                 0.85    0.57                             NA      NA      0.00       0.157               NA                  NA
                  rs1059491                                          Asn235Thr             A (36.08)                                               C                                 96.49   93.69                            NA      NA      **6.78**   NA                  NA                  NA

^a^ Minor allele frequencies were taken from the European cohort of the exome variant server (<http://evs.gs.washington.edu/EVS/>).

^b^ 355 family based trios (extremely obese index patient with both biological parents), transmission disequilibrium test.

^c^ 423 underweight or normal weight adults and 1,873 extremely obese children and adolescents, Fisher's exact test.

NA: not available. Data on *SH2B1* are obtained from our previous publication on a mutation screen in *SH2B1* \[[@pone.0125660.ref014]\] and displayed here to give a full overview on the mutations detected in the chromosomal region chr16p11.2 in the 95 screened individuals. The effect allele frequencies refer to the frequencies of the over-transmitted alleles in either the indexes or the parents. In case the variant was mono allelic in the analyzed sample (rs145008170), effect alleles could not be determined. For rs1059491, the p-value is not reported as the variant displayed a high Mendelian error rate (marked in bold). The high sequence similarity of *SULT1A1* and *SULT1A2* probably lead to congruent genotyping of the same variant Asn235Thr (rs1059491 and rs35728980, respectively) in both genes at the same time, despite choosing probes that were unique in the human genome (<http://genome.ucsc.edu/>).

\*Variant rs368546180: *APOBR* Thr321_Gly329del9was only detected in the screening sample and not in the independent study groups

The remaining nine variants were located in the un-translated region (UTR) or intronic regions or were synonymous (rs74949322: c.57+50C\>T, rs151233: p.Leu22 =, rs149271: p.Glu170 =, rs180744: p.Gln553 =, rs151174: p.Gly560 =, rs40831: p.Ala686 =, rs61738759: p.Pro1012 =, rs40833: c.\*218C\>G and rs142786317: c.\*118\_\*119delCA; [S1 Table](#pone.0125660.s001){ref-type="supplementary-material"}). *In silico* analysis showed that the infrequent alleles at these variants caused changes of either transcription factor binding sites splicing enhancer and silencer binding sites, or both ([S1 Table](#pone.0125660.s001){ref-type="supplementary-material"}).

SULT1A1 {#sec014}
-------

Of the initially detected variants (7 non-synonymous, [S2 Data](#pone.0125660.s005){ref-type="supplementary-material"}) in the coding region of *SULT1A1* in 95 extremely obese children and adolescents, none could be confirmed with an independent method. A high sequence similarity between the *SULT1A* gene family allowed for unspecific amplification of several *SULT1A* genes for individuals in the mutation screen resulting in artifacts. Hence, apart from *SULT1A1* we also amplified one or more *SULT1* gene family members. So that a variant that seemed to be located in *SULT1A1* was in fact attributable to *SULT1A2*, where it represents the wild type allele (see [S2 Data](#pone.0125660.s005){ref-type="supplementary-material"} and [S2 Table](#pone.0125660.s002){ref-type="supplementary-material"} for more detail). For the variant Met1Val, which could not be explained by one of the other *SULT1A* family members, two independent genotyping methods could not replicate our initial uni-directional Sanger-resequencing finding. We hence deemed this variant an artifact.

For the synonymous variants in *SULT1A1*, *in silico* predictions varied. All variants were predicted to change splicing enhancer and silencers, or to directly affect splice sites or transcription factor binding sites ([S1 Table](#pone.0125660.s001){ref-type="supplementary-material"}). Particularly for the variant p.Pro200 = (rs3176926), both changes in the binding domains of splicing regulators as well for the transcription factor AML-1 were predicted.

SULT1A2 {#sec015}
-------

In *SULT1A2* seven non-synonymous SNPs were detected (rs4149403: p.Ile7Thr, rs10797300: p.Pro19Leu, rs145008170: p.Ser44Asn, rs4987024: p.Tyr62Phe, rs142241142: p.Ala164Val, rs1059491: p.Asn235Thr, rs75191166: p.Lys282Gly); two synonymous SNPs (rs1690407: p.Ser8 =, rs139896537: p.Ala164 =; [S1 Table](#pone.0125660.s001){ref-type="supplementary-material"}), and five non-coding variants (rs4149406, rs3743963, rs710410, rs762634, rs145790611; [S1 Table](#pone.0125660.s001){ref-type="supplementary-material"}) were also identified.

For the non-conservative, non-synonymous SNP rs1136703: p.Ile7Thr (c.20T/C), *in silico* analyses did not predict a functional effect ([Table 2](#pone.0125660.t002){ref-type="table"}). For rs10797300: p.Pro19Leu (c.56C/T), *in silico* programs predicted a functional modification (PolyPhen2 and PANTHER, [Table 2](#pone.0125660.t002){ref-type="table"}). The conservative non-synonymous polymorphism rs145008170: p.Ser44Asn (c.131G/A) is located close to Lys48, which is relevant for binding of the xenobiotic p-nitrophenol to the binding pocket of SULT1A2. *In silico* analyses predicted a "non-neutral" (SNAP) or "deleterious" (PANTHER; [Table 2](#pone.0125660.t002){ref-type="table"}) functional change. The infrequent missense variants rs4987024: p.Tyr62Phe (c.185A/T) and rs142241142: p.Ala164Val (c.491C/T) are non-conservative amino acid exchanges which are not located close to the binding pocket of SULT1A2. *In silico*, a higher probability of functional changes was predicted for p.Tyr62Phe than for p.Ala164Val (Poly Phen 2 "probably damaging"), although the analyses revealed mixed results ([Table 2](#pone.0125660.t002){ref-type="table"}). *In silico* prediction mostly interpreted the conservative SNP rs1059491: p.Asn235Thr (c.704A/C) as functionally relevant ("probably damaging" PolyPhen2, "non-neutral" SNAP and "deleterious" SIFT; [Table 2](#pone.0125660.t002){ref-type="table"}). None of the analyzed non-synonymous SNPs in *SULT1A2* showed association with obesity in 355 obesity trios (TDT; [Table 3](#pone.0125660.t003){ref-type="table"}).

*In silico* predictions vary for the two known synonymous SNPs (rs1690407: p.Ser8 =, rs139896537: p.Ala164 =) and the five non-coding variants (rs4149406: c.148+34T/C, rs3743963: c.500−19T/C, rs710410: c.\*7T/C, rs762634: c.\*14A\>G, rs145790611: c.241+39G/A). For each variant, at least a change in either transcription factor binding sites or splicing enhancer or silencer sites was predicted ([S1 Table](#pone.0125660.s001){ref-type="supplementary-material"}).

TUFM {#sec016}
----

In *TUFM*, the previously unknown variant c.3536C\>G was detected in the 3' untranslated region (previously unknown). In addition, non-coding intronic variants were detected (rs7187776: c.-55T\>C, rs4788099: c.817+13T\>C, rs8061877: c.248−18G\>A, and rs61737565: c.922+29C\>G). All five variants in *TUFM* are predicted to lead to altered splicing regulator or transcription factor binding sites ([S1 Table](#pone.0125660.s001){ref-type="supplementary-material"}). For rs8061877, the disruption of a transcription factor binding site was predicted (TFSearch and Consite), although for different transcription factors (SRY, HFH 2, HMG-IY; [S1 Table](#pone.0125660.s001){ref-type="supplementary-material"}). For the previously unknown variant g.28854194C/G, *in silico* prediction showed a change in splice enhancer binding sites and splicing silencer sites by three programs ([S1 Table](#pone.0125660.s001){ref-type="supplementary-material"}). Also, alterations in splice sites for this variant were predicted (Mutation Taster) despite the variant being in the non-coding 3' UTR of *TUFM*.

Discussion {#sec017}
==========

Previous studies on the causal variation underlying the obesity association of chr16p11.2 mainly focused on the *SH2B1* gene. Mutation screens in humans \[[@pone.0125660.ref014], [@pone.0125660.ref024], [@pone.0125660.ref025]\] have revealed a number of mutations that are too infrequent to explain the genome-wide association of the lead SNP with BMI and obesity. The coding variant rs7498665 (*SH2B1*: p.Thr484Ala) was identified in GWAS studies as lead obesity association signal for a linkage disequilibrium block encompassing 1 Mb. However, this SNP showed no functional effect on STAT3 mediated leptin signaling \[[@pone.0125660.ref014]\] or the phosphorylation of JAK1 or IRS1 in insulin signaling \[[@pone.0125660.ref025]\]. Hence, variants underlying the genome-wide significant finding may be located outside the *SH2B1* coding region, but in high LD with the original association signal as proposed by Speliotes et al. \[[@pone.0125660.ref002]\]. We therefore screened the coding region of *APOBR*, *SULT1A1*, *SULT1A2* and *TUFM* for mutations in 95 extremely obese German children and adolescents.

We identified 13 variants in the *APOBR* coding region, three of which were non-synonymous or deletions. These (rs180743: p.Pro428Ala, rs3833080: p.Gly369_Asp370del9, and rs368546180 p.Thr321_Gly329del9) were genotyped in our trios and case-control study groups. The variants p.Pro428Ala and p.Gly369_Asp370del9 are located close to each other; their LD is high (r^2^ = 0.98) and their minor alleles are associated with obesity in our sample (OR = 1.27, 95%CI: 1.09--1.47, p = 0.002; p~Bonferroni\ corrected~ = 0.026 and p = 0.003; p~Bonferroni\ corrected~ = 0.039, OR = 1.25, 95% CI: 1.08--1.45, respectively; [Table 3](#pone.0125660.t003){ref-type="table"}) As the LD and proximity of both polymorphisms with the initial lead SNP and the non-synonymous polymorphism rs7498665 (*SH2B1*: p.Thr484Ala) is very high, the obesity association of all variants are dependent signals. Conditional analysis increased all p-values for rs180743, rs3833080, and rs7498665 above 0.7, indicating high signal dependency. Previously association of the minor alleles of both variants with hypercholesterolemia had been described \[[@pone.0125660.ref029]\]. Of note, the hypercholesterolemia and obesity risk allele C of rs180743 was not associated with weight loss during a 1 year lifestyle intervention in children and adolescents \[[@pone.0125660.ref069]\] although the position of the SNP is conserved (conservation 66% over 29 species, ENSEMBL). The second deletion (rs368546180: p.Thr321_Gly329del9) was only detected once in our sample of 2,179 obese cases and 435 normal weight or lean controls. Hence, obesity association assessment was not possible. Although variant rs368546180 is in-frame and located in the repeat region of *APOBR* which has no predicted function \[[@pone.0125660.ref027]\], *in silico* prediction of the variant implicated a potentially reduced function ([Table 2](#pone.0125660.t002){ref-type="table"}).

Almost all initially screened individuals are homozygous carriers of obesity risk alleles at the rs180743 (p.Pro428Ala) and rs3833080 (p.Gly369_Asp370del9) polymorphisms. Our results suggest that an *in vitro* functional validation of both deletion rs3833080 and SNP rs180743 would be of interest. Brown et al \[[@pone.0125660.ref027]\] suggested a contribution to binding of the specific ligand apoB48 of the repeat region in which both variants are located, with alterations possibly leading to reduced uptake of chylomicrons (CMs) or CM remnants. This hypothesis could be tested by lipoprotein-uptake assays or ligand blotting, as suggested by Daniel et al. \[[@pone.0125660.ref070]\] and Brown et al. \[[@pone.0125660.ref027]\].

In *SULT1A2*, none of the variants was associated with obesity ([Table 3](#pone.0125660.t003){ref-type="table"}), so they do not contribute to our initial TDT finding although some of the variants were predicted to have functional effects. Of the detected missense variants, several have known *in vitro* functional effects on xenobiotic sulfonation, e.g. rs4149404 (p.Ile7Thr), rs10797300 (p.Pro19Ser), and rs1059491 (p.Asn235Thr \[[@pone.0125660.ref071]\]). Glatt et al. \[[@pone.0125660.ref039]\] reported an obesity association for the minor allele of *SULT1A1* rs141581853 p.Arg213His in *SULT1A1*; the variant was not detected in our screen. In contrast to *SULT1A1* which shows ubiquitous expression \[[@pone.0125660.ref039]\], the expression of *SULT1A2* is limited to liver, blood platelets, heart, brain and skin. Both sulfotransferases share their substrates \[[@pone.0125660.ref072]\]. Even if the detected variants entail biological functional changes at the protein level, other sulfotransferases can most likely compensate for the function of each other *in vivo* when only one sulfotransferase is affected \[[@pone.0125660.ref073]\].

In addition to these variants which directly affect the amino acid composition of the proteins, recent studies detected a cis-regulatory element (intronic SNP rs4788099 in *SH2B1*) which affects the expression of nearby genes (*TUFM*, coiled-coil domain containing 101 gene: *CCDC101*, Homo sapiens spinster homolog 1 gene: *SPNS1*, *SULT1A1* and sulfotransferase family, cytosolic, 1A, phenolpreferring, member 4 gene: *SULT1A4*) in B cells and monocytes \[[@pone.0125660.ref074]\]. In rodents, differential regulation of the central nervous expression of several genes on chr16p11.2 was shown in reaction to high caloric diets \[[@pone.0125660.ref040], [@pone.0125660.ref075]\]. The GWAS lead SNP rs7359397 also affects the expression of *SULT1A1*, *SPNS1* and *TUFM*, but not *SH2B1* in *cis*. Although the SNP alone only explained 0.0086% of the genetic variance of BMI, the expression changes elicited in the three genes raise this number to 0.5% \[[@pone.0125660.ref076]\]. These regulatory effects could also contribute to the BMI association signal at chr 16p11.2 in GWAS \[[@pone.0125660.ref002], [@pone.0125660.ref077], [@pone.0125660.ref078]\].

Conclusion {#sec018}
==========

In sum, of the five analyzed genes *SH2B1* and *APOBR* comprised non-synonymous variants associated with obesity. These variants had a medium to high minor allele frequency and were thus previously identified in larger cohorts and population based samples (i.e. 1000genomes and exome variant server). Low frequency variants with potentially major gene effects for weight regulation besides *SH2B1* p.βThr656Ile/γPro674Ser \[[@pone.0125660.ref014]\] were not detected.
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###### DNA sequence of APOBR at the position of Del2 (rs3833080 \[Ala345_Gly346delAlaGlyThrAlaSerGlyGlyGluGluAlaGly\]).

Several potential positions of the deletion are displayed below the wild type sequence of the repeat region. The sequence marked with rs3833080 is given in the SNP database of the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/snp/>).

(DOCX)

###### 

Click here for additional data file.

###### Multiple sequence alignment of SULT1A1, SULT1A2 SULT1A3 and SULT1A4.

The amino acid sequence of the alpha splice variants of SULT1A1 (ENSP00000378971), SULT1A2 (ENSG00000197165), SULT1A3 (ENSP00000346760) and SULT1A4 (ENSP00000378796) were aligned using the program T-Coffee (<http://www.ebi.ac.uk/Tools/msa/tcoffee/>). Here, an asterisk below the amino acid alignment marks complete sequence identity, while dots below the sequence mark amino acids that share similar side chains or charges. The positions of missense variants detected in the mutation screens are marked in yellow, green marks the variants that could not be verified with independent methods, red marks the variants rs35728980 and rs1059491 which encode Asn235Thr in both SULT1A1 and SULT1A2, respectively.
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###### Mutated positions in the obesity candidate genes of chr16p11.2 and regional overview.

The first picture shows the whole chromosomal region 16p11.2 is displayed with the genes with non-synonymous variants described in this manuscript marked with vertical lines. The underlying picture shows the obesity association signals of SNPs in the GIANT collective (Speliotes et al. 2010). After the whole chromosomal region for reference, the screened genes are depicted with the detected mutations and MAF in CEU according to dbSNP (<http://www.ncbi.nlm.nih.gov/projects/SNP/>). Here, the horizontal lines symbolize the introns while exons are marked with bars. Functional domains are also included in the graphs. The positions of the variants are indicated with vertical lines.
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